Compare IGIC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | DBVT |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | Jordan | France |
| Employees | N/A | 90 |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 948.8M |
| IPO Year | 2019 | 2014 |
| Metric | IGIC | DBVT |
|---|---|---|
| Price | $28.69 | $13.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $28.00 | ★ $32.04 |
| AVG Volume (30 Days) | 89.1K | ★ 275.2K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | $0.13 | $35.04 |
| Revenue Next Year | $2.54 | $2,360.78 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $20.82 | $8.51 |
| 52 Week High | $28.84 | $26.19 |
| Indicator | IGIC | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 63.36 | 32.26 |
| Support Level | $24.51 | $12.63 |
| Resistance Level | $28.84 | $14.68 |
| Average True Range (ATR) | 0.67 | 0.87 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 93.10 | 11.88 |
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.